Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative disorders of the central nervous system. Its news flow centers on the clinical and regulatory progress of its lead candidate, zervimesine (CT1812), an investigational oral pill in development for Alzheimer’s disease, dementia with Lewy bodies (DLB) and related conditions.
News updates from Cognition Therapeutics frequently cover milestones in its Phase 2 clinical programs. These include results and analyses from the SHINE study in mild-to-moderate Alzheimer’s disease, the SHIMMER study in mild-to-moderate DLB, and the START study in early Alzheimer’s disease. Articles describe safety and tolerability outcomes, changes in cognition and function measured by validated scales, and exploratory findings in behavioral, movement and neuropsychiatric domains.
Investors following CGTX news also see announcements about expanded access programs for zervimesine in DLB, collaborations with organizations such as the Alzheimer’s Clinical Trials Consortium, and substantial grant support from the National Institute on Aging of the National Institutes of Health. Regulatory and scientific updates, such as end-of-Phase 2 discussions with the U.S. Food and Drug Administration, Type C meeting plans, and presentations at major Alzheimer’s disease conferences, are regular features of the company’s news cycle.
In addition, Cognition Therapeutics issues press releases on financing transactions, including registered direct offerings of common stock and at-the-market equity programs, which provide context on how it funds ongoing and planned studies. For readers tracking CGTX, this news page consolidates clinical, regulatory, scientific and capital markets developments related to zervimesine and the company’s broader neurodegenerative disease pipeline.
Cognition Therapeutics (CGTX) is showcasing findings from its clinical development program for CT1812, a sigma-2 receptor modulator targeting Alzheimer's disease, at the AD/PD™ 2022 conference in Barcelona from March 15-20, 2022. Results from the Phase 1b SNAP study indicate significant beta amyloid oligomer displacement into cerebrospinal fluid after CT1812 administration, contrasting with placebo results. Additionally, preliminary findings from the Phase 2 SHINE study highlight potential pharmacodynamic biomarkers linked to Alzheimer's treatment. Full SNAP results will be published in a peer-reviewed journal later this year.
Cognition Therapeutics (Nasdaq: CGTX) announces CEO Lisa Ricciardi's participation in two healthcare conferences. The Oppenheimer 32nd Annual Healthcare Conference will take place on March 16, 2022, at 4:00 p.m. ET, with a live webcast available for 90 days. The Sachs Neuroscience Innovation Forum, focusing on Alzheimer's and dementia, is scheduled for March 22, 2022, at 10:00 a.m. ET, also offering live and on-demand access for registered participants. One-on-one meetings with Ricciardi can be scheduled through event representatives.
Cognition Therapeutics (Nasdaq: CGTX) announced that Anthony Caggiano, M.D., Ph.D., will participate in the BIO CEO & Investor Conference on February 15, 2022, discussing neurodegenerative therapeutics. This panel aims to explore innovative partnerships in the field following a significant investment surge in neuroscience in 2020. Dr. Caggiano emphasized the renewed interest in therapies targeting biological pathways in neurological diseases, highlighting their sigma-2 receptor modulators. The event will be webcasted for registered attendees.
Cognition Therapeutics (Nasdaq: CGTX) announced significant achievements for 2021, including an upsized IPO that generated approximately $52 million and $45 million in grants from the National Institute on Aging for clinical studies. The company appointed new leadership for R&D and expanded its clinical pipeline, demonstrating clinical engagement in Alzheimer's and other neurodegenerative diseases. Looking ahead, Cognition aims to advance multiple studies funded by substantial grants and deliver new therapeutics to enhance shareholder value in 2022.
Cognition Therapeutics (NASDAQ: CGTX) has received a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research. This funding will support preclinical studies of two sigma-2 receptor modulators in animal models of Parkinson's disease, led by VP of research Mary E. Hamby, Ph.D. The studies aim to develop disease-modifying therapies for Parkinson's, where current options are lacking. CEO Anthony Caggiano emphasized the potential of σ-2 receptor targeting to impact disease progression biomarkers.
Cognition Therapeutics (Nasdaq: CGTX) announced that Lisa Ricciardi, CEO, will participate as a panelist in a virtual discussion titled, "Aduhelm: Stimulating the Next Generation of AD Treatment" on January 11, 2022, from 8:00 to 9:00 a.m. PT.
The panel focuses on the evolving investment landscape in Alzheimer's disease treatments, featuring CEOs from five companies in the sector. Cognition's key product, CT1812, is in Phase 2 development and has received FDA Fast Track designation for Alzheimer's.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) will hold a virtual R&D symposium on December 7, 2021, from 10:00 am to 12:00 pm ET. The event will focus on dementia with Lewy bodies (DLB), featuring presentations by experts from the DLB community, including insights on treatment and patient burden.
Cognition's management will discuss advancing their small molecule sigma-2 modulator for DLB. Registration is available on their website, and a live webcast will be provided.
Cognition Therapeutics (Nasdaq: CGTX) announced significant financial results for the third quarter ended September 30, 2021, following its upsized IPO which raised approximately $52 million. The firm received NIA grants totaling $43.6 million to support clinical studies for its lead candidate, CT1812, targeting mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies. They reported a net loss of $5.0 million for Q3, with increased R&D expenses of 8.1% and overall optimistic projections for clinical advancements. The firm maintains a cash reserve of $8.3 million and positive funding outlook for the next 24 months.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has closed the sale of 565,217 additional shares of common stock following the full exercise of the underwriters' over-allotment option related to its initial public offering. The shares were sold at $12.00 each, raising approximately $6.8 million before expenses. With this over-allotment, the total offering comprises 4,333,333 shares, generating about $52 million in gross proceeds. The IPO commenced trading on October 8, 2021.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced the appointment of Ellen B. Richstone to its board of directors, where she will chair the audit committee. Richstone brings extensive experience from Fortune 500 companies and board positions in manufacturing and technology. Her leadership in finance, operations, and over 35 acquisitions, totaling $1 billion raised, positions her to enhance Cognition's strategic direction. Richstone's academic credentials include degrees from Scripps College and Tufts University, and she has been recognized for her governance contributions.
FAQ
What is the current stock price of COGNITION THERAPEUTICS (CGTX)?
What is the market cap of COGNITION THERAPEUTICS (CGTX)?
